Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
Oncotarget|February 1, 2018
Multi-color RGB marking enables clonality assessment of liver tumors in a murine xenograft modelMichael Thomaschewski, Kristoffer Riecken, Ludmilla Unrau, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 29, 2013
Transduction of fetal mice with a feline lentiviral vector induces liver tumors which exhibit an E2F activation signatureReba Condiotti, Daniel Goldenberg, Hilla Giladi, et al.
Journal of Hepatology|March 27, 2025
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trialsChanghoon Yoo, Anna Saborowski, Jaewon Hyung, et al.
Scientific Reports|November 27, 2023
EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinomaLorenz Kocheise, Martin Schoenlein, Berit Behrends, et al.
United European Gastroenterology Journal|March 8, 2018
Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic diseaseMartha M Kirstein, Torsten Voigtländer, Nora Schweitzer, et al.
Gastroenterology|August 2, 2016
Inflammation-Induced Expression and Secretion of MicroRNA 122 Leads to Reduced Blood Levels of Kidney-Derived Erythropoietin and AnemiaMila Rivkin, Alina Simerzin, Elina Zorde-Khvalevsky, et al.
BMC Cancer|November 23, 2020
Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtypeJenny Krause, Johann von Felden, Christian Casar, et al.
The Lancet. Gastroenterology & Hepatology|June 13, 2024
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trialArndt Vogel, Anna Saborowski, Patrick Wenzel, et al.
European Radiology|May 23, 2025
Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAROsman Öcal, Christoph Johannes Zech, Maria Antonietta Bali, et al.
Alimentary Pharmacology & Therapeutics|April 14, 2019
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohortBernhard Scheiner, Martha M Kirstein, Florian Hucke, et al.
Pageof 8